(CercleFinance.com) – Pharnext announces that it has received two binding offers with a view to signing an agreement to develop ‘PXT3003’, its most advanced drug candidate currently in a pivotal Phase III clinical study in Charcot’s disease. Marie-Tooth type 1A (CMT1A), a rare disabling peripheral neuropathy, at more than 250 ME.
One of the offers concerns a licensing agreement with limited geographic exclusivity in the United States and Europe, allowing Pharnext to subsequently initiate new negotiations in other territories.
The other offer concerns a purchase of the entire intellectual property of PXT3003 and the attached contracts with a view to global exploitation, outside Chinese territory.
Depending on the different projections of future revenues linked to sales of the drug, total revenues could reach between 250 ME and up to 800 ME for Pharnext over the entire life of the rights.
Furthermore, in order to cover its short-term financing needs and allow the peaceful continuation of the process of valorization of its main asset, Pharnext announces that it has asked GTO 13 and obtained from them to subscribe to additional financing of 2.5 ME over the next few days by the issuance of OCEANE-BSA.
Copyright (c) 2023 CercleFinance.com. All rights reserved.